Resource use and costs associated with diabetic macular edema in elderly persons

Archives of Ophthalmology

Volumn 126, Issue 12, 2008, Pages 1748-1754

  Shea, Alisa M ^a   Curtis, Lesley H ^a,b   Hammill, Bradley G ^a   Kowalski, Jonathan W ^d   Ravelo, Arliene ^b   Lee, Paul P ^d   Sloan, Frank A ^c   Schulman, Kevin A ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE;

AGED; ARTICLE; COMORBIDITY; CONTROL GROUP; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENCE ANGIOGRAPHY; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; LASER COAGULATION; MALE; MEDICARE; OPTICAL COHERENCE TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; DIABETIC RETINOPATHY; ECONOMICS; HEALTH CARE PLANNING; HEALTH SERVICES RESEARCH; INSURANCE; MEDICAL FEE; RETINA MACULA EDEMA; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; DIABETIC RETINOPATHY; FEE-FOR-SERVICE PLANS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HEALTH RESOURCES; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE CLAIM REVIEW; LASER COAGULATION; MACULAR EDEMA; MALE; MEDICARE PART A; TOMOGRAPHY, OPTICAL COHERENCE; UNITED STATES;

EID: 58149240462     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.126.12.1748     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552-563.
3. Centers for Disease Control and Prevention. Public health focus: prevention of blindness associated with diabetic retinopathy. MMWR Morb Mortal Wkly Rep. 1993;42(10):191-195.
4. American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy 2003. San Francisco, CA: American Academy of Ophthalmology; 2003.
5. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye. 2004;18(10):963-983.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.
7. Klein R, Klein BE, Moss SE. The epidemiology of ocular problems in diabetes mellitus. In: Ferman SS, ed. Ocular Problems in Diabetes Mellitus. Boston, MA: Blackwell Scientific Publications; 1991:1-51.
8. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760.
9. Salm M, Belsky D, Sloan FA. Trends in cost of major eye diseases to Medicare, 1991 to 2000. Am J Ophthalmol. 2006;142(6):976-982.
10. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124(1 pt 2):164-169.
11. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889-896.
12. Bearelly S, Mruthyunjaya P, Tzeng JP, et al. Identification of patients with diabetic macular edema from claims data: a validation study. Arch Ophthalmol. 2008;126(7):986-989.
13. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43(5):480-485.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
15. Zysk AM, Nguyen FT, Oldenburg AL, Marks DL, Boppart SA. Optical coherence tomography: a review of clinical development from bench to bedside. J Biomed Opt. 2007;12(5):051403.
16. Browning DJ, McOwen MD, Bowen RM Jr, O'Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology. 2004;111(4):712-715.
17. Coker JG, Duker JS. Macular disease and optical coherence tomography. Curr Opin Ophthalmol. 1996;7(3):33-38.
18. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105(2):360-370.
19. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113(8):1019-1029.
20. Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995;102(2):217-229.
21. Ip MS. Intravitreal triamcinolone for the treatment of diabetic macular edema. In: Focus on Diabetic Retinopathy. Wayne, PA: Retina Today; 2007:41-47.
22. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121(1):57-61.
23. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-927.
24. Ip MS. Intravitreal injection of triamcinolone: an emerging treatment for diabetic macular edema. Diabetes Care. 2004;27(7):1794-1797.
25. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12):1796- 1806.
26. Mohamed Q, Gillies MD, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902-916.
27. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(suppl 1):S84-S87.
28. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647-661.
29. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998;116(3):297-303.
30. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR; UK Prospective Diabetes Study (IKPDS) group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18(3):178-184.
31. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-983.
32. Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal prevalence of major eye diseases. Arch Ophthalmol. 2003;121(9):1303-1310.
33. Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Incidence of exudative agerelated macular degeneration among elderly Americans. Ophthalmology. 2003;110(8):1534-1539.
34. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29(6):1263-1268.